Literature DB >> 2319465

The antiseizure activity of dihydropyridine calcium channel antagonists in the conscious rat.

M A Morón1, C W Stevens, T L Yaksh.   

Abstract

By using a rat seizure model, a comparison of the antiseizure activity of 12 dihydropyridine calcium channel antagonists (administered i.c.v.) to their binding affinities for the neuronal site known to regulate L-type calcium channels was made. For these dihydropyridine calcium channel antagonists a correlation between physiologic activity and binding affinities would provide evidence that these agents exert their antiseizure actions via a mechanism involving a binding site that regulates L-type neuronal calcium channels. Despite i.c.v. administration, a parallel in antiseizure activity and binding affinities could not be demonstrated precisely, suggesting that the dihydropyridines may be exerting their antiseizure activity by more than just simple neuronal calcium channel blockade.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2319465

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

Review 1.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 2.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

3.  Facilitation of shuttle-box avoidance behaviour in mice treated with nifedipine in combination with amphetamine.

Authors:  J Vetulani; M Battaglia; C Castellano; M Sansone
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Identification of marine neuroactive molecules in behaviour-based screens in the larval zebrafish.

Authors:  Si-Mei Long; Feng-Yin Liang; Qi Wu; Xi-Lin Lu; Xiao-Li Yao; Shi-Chang Li; Jing Li; Huanxing Su; Ji-Yan Pang; Zhong Pei
Journal:  Mar Drugs       Date:  2014-05-30       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.